Targeting c-Jun and JunB proteins as potential anticancer cell therapy

The activating protein-1 transcription factor, in particular the Jun proteins play critical roles in the regulation of cell proliferation and tumor progression. To study the potential clinical relevance of interfering with JunB expression, we generated retroviruses expressing short hairpin RNA. Reduction of JunB levels causes increased proliferation and tumorigenicity in wild-type murine fibroblasts, whereas in c-Jun knockout cells p53-independent cell cycle arrest and apoptosis are induced. Using melanoma-derived B16-F10 cancer cells the combination of JunB knockdown and c-Jun/JNK inactivation leads to cell cycle arrest and apoptosis-inducing factor-dependent apoptosis. Furthermore, the combined treatment extends survival of mice inoculated with the tumor cells. These results indicate that in the absence of c-Jun, JunB can act as a tumor promoter and inactivation of both, c-Jun and JunB, could provide a valuable strategy for antitumor intervention.

[1]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[2]  L. Galluzzi,et al.  Mitochondria as therapeutic targets for cancer chemotherapy , 2006, Oncogene.

[3]  B. Wong,et al.  Induction of apoptosis and cell cycle arrest by a specific c-Jun NH2-terminal kinase (JNK) inhibitor, SP-600125, in gastrointestinal cancers. , 2006, Cancer letters.

[4]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.

[5]  M. Herlyn,et al.  Rewired ERK-JNK signaling pathways in melanoma. , 2007, Cancer Cell.

[6]  C. Jasmin,et al.  CD44 ligation induces caspase-independent cell death via a novel calpain/AIF pathway in human erythroleukemia cells , 2006, Oncogene.

[7]  David W. Anderson,et al.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Whittaker,et al.  Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. , 2003, Blood.

[9]  G. T. Bowden,et al.  Regulation of the transcription factor AP‐1 in benign and malignant mouse keratinocyte cells , 1997, Molecular carcinogenesis.

[10]  Ruedi Aebersold,et al.  Molecular characterization of mitochondrial apoptosis-inducing factor , 1999, Nature.

[11]  E. Wagner,et al.  JunB can substitute for Jun in mouse development and cell proliferation , 2002, Nature Genetics.

[12]  I. Weissman,et al.  JunB Deficiency Leads to a Myeloproliferative Disorder Arising from Hematopoietic Stem Cells , 2004, Cell.

[13]  Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms. , 2005, American journal of clinical pathology.

[14]  E. Wagner,et al.  Chronic Myeloid Leukemia with Increased Granulocyte Progenitors in Mice Lacking JunB Expression in the Myeloid Lineage , 2001, Cell.

[15]  C. Rhee,et al.  Caspase-Independent Cell Death by Arsenic Trioxide in Human Cervical Cancer Cells , 2004, Cancer Research.

[16]  M. Karin,et al.  JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. , 1993, Genes & development.

[17]  Yong-Yeon Cho,et al.  The tumor suppressor p16INK4a prevents cell transformation through inhibition of c-Jun phosphorylation and AP-1 activity , 2005, Nature Structural &Molecular Biology.

[18]  Axel Behrens,et al.  Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development , 2005, Nature.

[19]  E. Wagner,et al.  Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. , 2006, The international journal of biochemistry & cell biology.

[20]  T. Libermann,et al.  Targeting transcription factors for cancer gene therapy. , 2006, Current gene therapy.

[21]  Amy M Mingo-Sion,et al.  Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells , 2004, Oncogene.

[22]  Jan-Gowth Chang,et al.  JunB gene expression is inactivated by methylation in chronic myeloid leukemia. , 2003, Blood.

[23]  T. Dawson,et al.  Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor , 2002, Science.

[24]  E. Wagner,et al.  Liver Tumor Development c-Jun Antagonizes the Proapoptotic Activity of p53 , 2003, Cell.

[25]  G. Kroemer,et al.  Mitochondrial permeability transition triggers lymphocyte apoptosis. , 1996, Journal of immunology.

[26]  E. Wagner,et al.  JunB inhibits proliferation and transformation in B-lymphoid cells. , 2003, Blood.

[27]  Roger G. Chui,et al.  c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. , 2005, Blood.

[28]  M. Karin,et al.  Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun , 1989, Cell.

[29]  B. Spiegelman,et al.  Common DNA binding site for Fos protein complexesand transcription factor AP-1 , 1988, Cell.

[30]  E. Wagner,et al.  Control of cell cycle progression by c-Jun is p53 dependent. , 1999, Genes & development.

[31]  T. Curran,et al.  FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA , 1982, Journal of virology.

[32]  P. Vogt.  Fortuitous convergences: the beginnings of JUN , 2002, Nature Reviews Cancer.

[33]  R. Bernards,et al.  Stable suppression of tumorigenicity by virus-mediated RNA interference. , 2002, Cancer cell.

[34]  R. Tjian,et al.  Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. , 1987, Science.

[35]  M. Kulesz-Martin,et al.  Oncogene activation and tumor suppressor gene inactivation during multistage mouse skin carcinogenesis. , 1994, Cancer research.

[36]  O. Mariani,et al.  JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. , 2007, Cancer cell.

[37]  M. Izquierdo,et al.  RNA interference against Hec1 inhibits tumor growth in vivo , 2006, Gene Therapy.

[38]  T. Curran,et al.  Candidate product of the FBJ murine osteosarcoma virus oncogene: characterization of a 55,000-dalton phosphoprotein , 1982, Journal of virology.

[39]  Paul J van Diest,et al.  c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. , 2006, Human pathology.

[40]  G. Rassidakis,et al.  JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis , 2005, Modern Pathology.

[41]  G. K. Bilter,et al.  Inhibition of Tumor Growth, Angiogenesis, and Tumor Cell Proliferation by a Small Molecule Inhibitor of c-Jun N-terminal Kinase , 2005, Journal of Pharmacology and Experimental Therapeutics.